Literature DB >> 16461743

Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation.

Matthijs Kramer1, Mihai G Netea, Dirk J de Jong, Bart Jan Kullberg, Gosse J Adema.   

Abstract

The nucleotide oligomerization domain 2 (NOD2) 3020insC (NOD2fs) mutation increases susceptibility to Crohn's disease (CD), but the mechanism remains controversial. Loss-of-function and gain-of-function phenotypes have been described as a result of NOD2fs. Here, we show that dendritic cells (DC) derived from CD patients homozygous for this mutation respond normally to purified Toll-like receptor (TLR) ligands but fail to up-regulate the costimulatory molecules CD80 and CD86 in response to the NOD2 ligand muramyl dipeptide (MDP). Moreover, they lack MDP-induced enhancement of TLR-mediated tumor necrosis factor alpha, interleukin (IL)-12, and IL-10 production, which is observed in control DC with intact NOD2. These data indicate that the NOD2fs mutation results in a loss-of-function phenotype in human myeloid DC and imply decreased immune regulation by IL-10 as a possible mechanism for this mutation in CD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461743     DOI: 10.1189/jlb.0805484

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  Is Crohn's disease due to defective immunity?

Authors:  J R Korzenik
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 2.  Innate immunity in inflammatory bowel disease.

Authors:  Jesus-K Yamamoto-Furusho; Daniel-K Podolsky
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

Review 3.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases.

Authors:  Jeanette M Wilmanski; Tanja Petnicki-Ocwieja; Koichi S Kobayashi
Journal:  J Leukoc Biol       Date:  2007-09-17       Impact factor: 4.962

4.  Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis.

Authors:  Grit Waitz; Sebastian Petermann; Stefan Liebe; Joerg Emmrich; Wolfgang Ramlow
Journal:  Dig Dis Sci       Date:  2008-02-06       Impact factor: 3.199

Review 5.  Unleashing the therapeutic potential of NOD-like receptors.

Authors:  Kaoru Geddes; João G Magalhães; Stephen E Girardin
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 6.  Function of Nod-like receptors in microbial recognition and host defense.

Authors:  Luigi Franchi; Neil Warner; Kyle Viani; Gabriel Nuñez
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

Review 7.  Inflammatory bowel disease: genetic and epidemiologic considerations.

Authors:  Judy H Cho
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Simultaneous deletion of NOD1 and NOD2 inhibits in vitro alloresponses but does not prevent allograft rejection.

Authors:  Sashi G Kasimsetty; Andrew T Scheinok; Alana A Shigeoka; Dianne B McKay
Journal:  Immunobiology       Date:  2015-06-29       Impact factor: 3.144

9.  Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease.

Authors:  Mirjam Bueno de Mesquita; Marc Ferrante; Liesbet Henckaerts; Marie Joossens; Virginie Janssens; Tibor Hlavaty; Marie Pierik; Sofie Joossens; Nele Van Schuerbeek; Gert Van Assche; Paul Rutgeerts; Severine Vermeire; Ilse Hoffman
Journal:  Eur J Pediatr       Date:  2008-08-01       Impact factor: 3.183

Review 10.  NOD-like receptors and inflammation.

Authors:  Rebeccah J Mathews; Michael B Sprakes; Michael F McDermott
Journal:  Arthritis Res Ther       Date:  2008-11-25       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.